.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Argus Health
Baxter
UBS
Cerilliant
Cipla
Julphar
Chubb
US Department of Justice
Teva

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,444,652

« Back to Dashboard

Which drugs does patent 6,444,652 protect, and when does it expire?


Patent 6,444,652 protects TYZEKA and is included in two NDAs.

This patent has forty-four patent family members in twenty countries.

Summary for Patent: 6,444,652

Title: .beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B
Abstract:This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside has the formula: ##STR1## wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.
Inventor(s): Gosselin; Gilles (Montpellier, FR), Imbach; Jean-Louis (Montpellier, FR), Bryant; Martin L. (Carlisle, MA)
Assignee: Novirio Pharmaceuticals Limited (Grand Cayman, CY) Centre National da la Recherche Scientifique (Paris, FR)
Application Number:09/459,150
Patent Claim Types:
see list of patent claims
Use; Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis
TYZEKA
telbivudine
TABLET;ORAL022011-001Oct 25, 2006RXYesYes► Subscribe► Subscribe TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE
Novartis
TYZEKA
telbivudine
SOLUTION;ORAL022154-001Apr 28, 2009DISCNNoNo► Subscribe► Subscribe TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,444,652

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,011,195,922► Subscribe
6,569,837 .beta.-L-2'-deoxy pyrimidine nucleosides for the treatment of hepatitis B► Subscribe
6,946,450 .beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B► Subscribe
9,290,533.beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B► Subscribe
7,795,238.beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B► Subscribe
7,304,043.beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B► Subscribe
6,566,344 .beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B► Subscribe
6,395,716 .beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,444,652

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Singapore132498► Subscribe
Russian Federation2424016► Subscribe
Russian Federation2006147216► Subscribe
Portugal2415776► Subscribe
Russian Federation2300381► Subscribe
Portugal1431304► Subscribe
Netherlands300286► Subscribe
MexicoPA01001507► Subscribe
South Korea100702230► Subscribe
Luxembourg91348► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Teva
Accenture
Harvard Business School
US Department of Justice
QuintilesIMS
Citi
Dow
US Army
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot